Perrigo Squares Off With Dr. Reddy’s In Lansoprazole Launch
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA denied Perrigo’s petition that had sought to block Dr. Reddy’s ANDA for generic Prevacid 24HR because it used bioequivalence data for the proton pump inhibitor’s Rx version. Competition between the firms is intensifying as Dr. Reddy’s expands its U.S. OTC presence.